BioWorld

March 24, 2006

Pfizer Licenses, Invests In Noxxon’s Spiegelmer Drugs

Since its founding in 1997, German company Noxxon Pharma AG has flown low, working to develop products based on its Spiegelmer technology. (BioWorld Today) Read More

CombinatoRx Privately Raises $48M For Pipeline Of Phase IIs

New Method Tests If H5N1 Can Learn How To Spread

Quaker BioVentures: Southeast Will Be Next Big Biotech Region

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...